Cribriform Prostate Cancer: Clinical Pathologic and Molecular Considerations

Area of Science:

• Urology
• Oncology
• Genetics

Background:

• Intraductal cribriform (IDC) and invasive cribriform prostate cancer morphologies are linked to adverse clinical outcomes.
• Previous studies suggested an association between cribriform histology and germline mutations in DNA repair genes, notably BRCA2.
• This association has influenced clinical guidelines, recommending germline testing for patients with cribriform features.

Purpose of the Study:

• To review the current understanding of intraductal cribriform and invasive cribriform prostate cancer.
• To emphasize the clinical outcomes associated with these aggressive prostate cancer morphologies.
• To highlight the molecular alterations implicated in cribriform prostate cancer.

Main Methods:

• Literature review of studies investigating intraductal cribriform and invasive cribriform prostate cancer.
• Analysis of clinical outcomes and prognostic significance of cribriform morphologies.
• Summary of molecular alterations, including germline mutations, associated with cribriform prostate cancer.

Main Results:

• Cribriform morphologies in prostate cancer are associated with worse patient outcomes.
• The link between cribriform histology and germline DNA repair gene mutations (e.g., BRCA2) is debated, with conflicting evidence from retrospective and prospective studies.
• Understanding the molecular drivers of cribriform prostate cancer is crucial for refining clinical management.

Conclusions:

• A deeper understanding of the molecular basis of cribriform prostate cancer is essential for accurate clinical decision-making.
• Further research is warranted to reconcile conflicting findings and elucidate the precise role of genetic alterations in cribriform morphology.
• Clarifying these aspects will improve risk stratification and treatment strategies for patients with aggressive prostate cancer.